title: A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2.
abstract: HHLA2 is a newly identified B7 family member that modulates T-cell functions through interaction with TMIGD2 and possibly a second receptor, with coinhibition in two studies and costimulation in one study. HHLA2 is expressed on a variety of human cancers, and its coinhibitory function makes it a candidate for cancer immunotherapy.
authors: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
authors: Yanping
authors: Y
authors: Xiao
authors: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Gordon_Freeman@dfci.harvard.edu.
authors: Gordon J
authors: GJ
authors: Freeman
mesh_terms: D000818:Animals; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism*; D064726:Triple Negative Breast Neoplasms / Q000378:metabolism*
chemical_list: D007136:Immunoglobulins